Vischer advises Oculis on its public listing on Nasdaq

Oculis Holding, a global biopharmaceutical company, purposefully driven to save sight and improve eye care, listed its shares on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp. (“EBAC”). At closing, Oculis had a pro-forma enterprise value of approximately USD 220m and a cash balance exceeding USD 117m prior to payment of final transaction costs.

Oculis is supported by leading new and existing institutional investors in the upsized PIPE financing including LSP 7, funds managed by Tekla Capital Management, Earlybird, Novartis Venture Fund, Pivotal Life Sciences, and VI Partners, among others.

VISCHER has advised as Swiss counsel with a team led by Matthias Staehelin (partner, pictured left) and Vincent Reardon (managing associate, pictured right) with Balthasar Müller, Timothy Woodtli, Natacha Tang, Sophie Zimmermann (all corporate/m&a) as well as Nadia Tarolli and Adrian Briner (both tax).